DNAI7: A Potential Cancer Drug Target and Biomarker (G55259)

Target Name: DNAI7

NCBI ID: G55259

DNAI7

DNAI7: A Potential Cancer Drug Target and Biomarker

DNAI7 (DNA-binding inhibitor 7) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and gastrointestinal tract. It is a member of the superfamily of DNA-binding proteins, which includes proteins that interact with DNA to regulate gene expression and DNA replication. In recent years, researchers have become increasingly interested in DNAI7 as a potential drug target or biomarker for various diseases, including cancer.

At its core, DNAI7 functions as a protein that binds to specific DNA sequences, either in the context of a gene or the entire genome. This binding is critical for the regulation of gene expression, as well as the development and progression of cancer. In fact, DNAI7 has been shown to play a critical role in the regulation of cell proliferation and the development of cancer.

One of the key reasons for the interest in DNAI7 as a potential drug target is its potential to disrupt the formation of cancer cells. Studies have shown that DNAI7 can inhibit the growth and spread of cancer cells in a variety of models, including mouse models of breast, lung, and ovarian cancer. This is achieved through its ability to bind to and inhibit the activity of key transcription factors, which are responsible for regulating gene expression and cell growth.

In addition to its potential as a cancer drug, DNAI7 has also been shown to be a potential biomarker for the disease. Its expression has been detected in a variety of cancer types, including breast, lung, and ovarian cancer, and has been shown to be associated with poor prognosis in patients with these diseases. Furthermore, its expression has been linked to the development of various side effects associated with cancer treatment, such as fatigue, neurotoxicity, and cardiovascular disease.

Another promising aspect of DNAI7 is its potential to serve as a target for small molecules. Many drugs that are currently in use for cancer treatment work by binding to specific DNA-bound proteins and inhibiting their activity. DNAI7 has been shown to be a good candidate for small molecules that can inhibit its activity, potentially providing a new mechanism of action for cancer treatments.

In conclusion, DNAI7 is a protein that has the potential to be a drug target or biomarker for various diseases, including cancer. Its ability to bind to specific DNA sequences and its potential to disrupt the formation of cancer cells make it an attractive candidate for drug development. Furthermore, its potential as a biomarker for cancer and its potential to serve as a target for small molecules add to its growing list of potential applications in the field. As research continues to advance, the potential of DNAI7 as a drug target or biomarker for cancer will be further evaluated and understood.

Protein Name: Dynein Axonemal Intermediate Chain 7

Functions: Via its association with the multisubunit axonemal dynein complex, is potentially involved in the regulation of cilia function. May also act as a cell cycle regulator

The "DNAI7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAI7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets